NASDAQ: $TLX Today marks an important milestone in the ongoing effort to improve the diagnosis and management of prostate cancer. We are excited to share news regarding the initiation of dosing for the first U.S. patient in the pivotal BiPASS Phase 3 clinical trial. This study focuses on assessing the performance of a novel diagnostic…